Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24239951 | 0.89 | — | — | |
| SCHEMBL22844758 | 0.88 | SMN1; SMN2 (0.32) | SMN1; SMN2 | |
| SCHEMBL845474 | 0.78 | — | — | |
| SCHEMBL846083 | 0.78 | — | — | |
| SCHEMBL21029658 | 0.77 | SMN1; SMN2 (0.38) | SMN1; SMN2 | |
| SCHEMBL963596 | 0.74 | GPR119 (0.45) | — | |
| SCHEMBL23594112 | 0.73 | HTT (0.30) | — | |
| SCHEMBL25129794 | 0.73 | HTT (0.30) | — | |
| SCHEMBL10204117 | 0.73 | HTT (0.30) | — | |
| SCHEMBL12257664 | 0.72 | SMN1; SMN2 (0.36) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12043833-B2 | Targeted compositions | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-07-23 | — | — | US | disclosed |
| US-12043833-B2 | Targeted compositions | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-07-23 | — | — | US | disclosed |
| US-20220062323-A1 | BIVALENT TARGETED CONJUGATES | ARBUTUS BIOPHARMA CORPORATION (CA) | 2022-03-03 | — | — | US | disclosed |
| US-20220031847-A1 | THERAPEUTIC METHODS | GENEVANT SCIENCES GMBH (CH) | 2022-02-03 | — | — | US | disclosed |
| US-20190160176-A1 | TARGETED NUCLEIC ACID CONJUGATE COMPOSITIONS | ARBUTUS BIOPHARMA CORPORATION (CA) | 2019-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190160176-A1 | TARGETED NUCLEIC ACID CONJUGATE COMPOSITIONS | HAVCR2, DCTD, POLRMT | SMN1; SMN2 2277/4885 |
| US-20220062323-A1 | BIVALENT TARGETED CONJUGATES | ERBB2, PCNA, MRE11 | SMN1; SMN2 1422/4885 |
| US-20220031847-A1 | THERAPEUTIC METHODS | NUP205, HNRNPH3, FUS | SMN1; SMN2 358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.